Serono's Oral Cladribine for the Treatment of Multiple Sclerosis Awarded Fast Track Status By FDA (RedNova)
GENEVA, Switzerland, September 21 /PRNewswire-FirstCall/ -- Serono (virt-x: SEO and NYSE: SRA) announced today that oral cladribine has been designated a Fast Track product by the US Food and Drug Administration (FDA). This designation covers patients with relapsing forms of multiple sclerosis.

Novartis receives additional EU approvals for Glivec (Pharmaceutical Business Review)
EU health authorities have granted Novartis AG additional approvals for its cancer drug Glivec.